欧洲近距离放射治疗现状 - GEC-ESTRO Brachy-HERO 调查

IF 2.7 3区医学 Q3 ONCOLOGY

Clinical and Translational Radiation Oncology Pub Date : 2024-11-02 DOI:10.1016/j.ctro.2024.100883

J.G. Johansen , I.M. Jürgenliemk-Schulz , H. Haddad , J.M. Hannoun-Levi , T.P. Hellebust , B. Guix , K. Loessl , B. Pieters , C. Rao , V. Strnad , A.E. Sturdza , L. Tagliaferri , Z. Takacsi-Nagy , E. Villafranca , P. Wojcieszek , A. Rembielak , P. Niehoff

{"title":"欧洲近距离放射治疗现状 - GEC-ESTRO Brachy-HERO 调查","authors":"J.G. Johansen , I.M. Jürgenliemk-Schulz , H. Haddad , J.M. Hannoun-Levi , T.P. Hellebust , B. Guix , K. Loessl , B. Pieters , C. Rao , V. Strnad , A.E. Sturdza , L. Tagliaferri , Z. Takacsi-Nagy , E. Villafranca , P. Wojcieszek , A. Rembielak , P. Niehoff","doi":"10.1016/j.ctro.2024.100883","DOIUrl":null,"url":null,"abstract":"<div><div>A survey regarding utilisation of brachytherapy was distributed to European brachytherapy professionals. Eighty replies from 26 countries were received, two of which were outside Europe. The replies showed that brachytherapy is still widely used. The main indications for brachytherapy are gynaecological and prostate cancer, with >80 % of the responding countries performing brachytherapy for these indications. There is on average one brachytherapy centre per 0.8 million inhabitants, ranging from 0.4 per million to 2.3 per million inhabitants. The organisation of brachytherapy on national levels also varies from country to country, with less than half of the countries having a central brachytherapy registry. All in all, the survey shows that brachytherapy still plays a role on modern radiotherapy, but the field could benefit from a stronger collaboration both nationally and internationally.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"50 ","pages":"Article 100883"},"PeriodicalIF":2.7000,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The current status of brachytherapy in Europe − A GEC-ESTRO Brachy-HERO survey\",\"authors\":\"J.G. Johansen , I.M. Jürgenliemk-Schulz , H. Haddad , J.M. Hannoun-Levi , T.P. Hellebust , B. Guix , K. Loessl , B. Pieters , C. Rao , V. Strnad , A.E. Sturdza , L. Tagliaferri , Z. Takacsi-Nagy , E. Villafranca , P. Wojcieszek , A. Rembielak , P. Niehoff\",\"doi\":\"10.1016/j.ctro.2024.100883\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>A survey regarding utilisation of brachytherapy was distributed to European brachytherapy professionals. Eighty replies from 26 countries were received, two of which were outside Europe. The replies showed that brachytherapy is still widely used. The main indications for brachytherapy are gynaecological and prostate cancer, with >80 % of the responding countries performing brachytherapy for these indications. There is on average one brachytherapy centre per 0.8 million inhabitants, ranging from 0.4 per million to 2.3 per million inhabitants. The organisation of brachytherapy on national levels also varies from country to country, with less than half of the countries having a central brachytherapy registry. All in all, the survey shows that brachytherapy still plays a role on modern radiotherapy, but the field could benefit from a stronger collaboration both nationally and internationally.</div></div>\",\"PeriodicalId\":10342,\"journal\":{\"name\":\"Clinical and Translational Radiation Oncology\",\"volume\":\"50 \",\"pages\":\"Article 100883\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-11-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Translational Radiation Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2405630824001605\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405630824001605","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

我们向欧洲近距离放射治疗专业人员发放了一份关于近距离放射治疗使用情况的调查问卷。共收到来自 26 个国家的 80 份回复，其中两份来自欧洲以外的国家。调查结果显示，近距离放射治疗仍在广泛使用。近距离放射治疗的主要适应症是妇科癌症和前列腺癌，80% 的受访国家针对这些适应症开展了近距离放射治疗。平均每 80 万居民就有一个近距离治疗中心，比例从每百万居民 0.4 个到 2.3 个不等。各国近距离治疗的组织情况也不尽相同，只有不到一半的国家拥有中央近距离治疗登记处。总之，调查显示近距离放射治疗在现代放射治疗中仍然发挥着重要作用，但这一领域可以从加强国内和国际合作中获益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The current status of brachytherapy in Europe − A GEC-ESTRO Brachy-HERO survey

A survey regarding utilisation of brachytherapy was distributed to European brachytherapy professionals. Eighty replies from 26 countries were received, two of which were outside Europe. The replies showed that brachytherapy is still widely used. The main indications for brachytherapy are gynaecological and prostate cancer, with >80 % of the responding countries performing brachytherapy for these indications. There is on average one brachytherapy centre per 0.8 million inhabitants, ranging from 0.4 per million to 2.3 per million inhabitants. The organisation of brachytherapy on national levels also varies from country to country, with less than half of the countries having a central brachytherapy registry. All in all, the survey shows that brachytherapy still plays a role on modern radiotherapy, but the field could benefit from a stronger collaboration both nationally and internationally.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical and Translational Radiation Oncology Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

5.30

自引率

3.20%

发文量

114

审稿时长

40 days